These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11436957)

  • 1. Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a reanalysis using drug-placebo and drug-drug response curve methodology.
    Faraone SV; Pliszka SR; Olvera RL; Skolnik R; Biederman J
    J Child Adolesc Psychopharmacol; 2001; 11(2):171-80. PubMed ID: 11436957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a drug-placebo and drug-drug response curve analysis of a naturalistic study.
    Faraone SV; Short EJ; Biederman J; Findling RL; Roe C; Manos MJ
    Int J Neuropsychopharmacol; 2002 Jun; 5(2):121-9. PubMed ID: 12135536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder.
    Pelham WE; Aronoff HR; Midlam JK; Shapiro CJ; Gnagy EM; Chronis AM; Onyango AN; Forehand G; Nguyen A; Waxmonsky J
    Pediatrics; 1999 Apr; 103(4):e43. PubMed ID: 10103335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder.
    Pliszka SR; Browne RG; Olvera RL; Wynne SK
    J Am Acad Child Adolesc Psychiatry; 2000 May; 39(5):619-26. PubMed ID: 10802980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis.
    Faraone SV; Biederman J; Roe C
    J Clin Psychopharmacol; 2002 Oct; 22(5):468-73. PubMed ID: 12352269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder.
    Pelham WE; Gnagy EM; Chronis AM; Burrows-MacLean L; Fabiano GA; Onyango AN; Meichenbaum DL; Williams A; Aronoff HR; Steiner RL
    Pediatrics; 1999 Dec; 104(6):1300-11. PubMed ID: 10585981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective comparison of Adderall and methylphenidate in the treatment of attention deficit hyperactivity disorder.
    Grcevich S; Rowane WA; Marcellino B; Sullivan-Hurst S
    J Child Adolesc Psychopharmacol; 2001; 11(1):35-41. PubMed ID: 11322743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
    Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effectiveness of methylphenidate and Adderall in school-age youths with attention-deficit/hyperactivity disorder.
    Manos MJ; Short EJ; Findling RL
    J Am Acad Child Adolesc Psychiatry; 1999 Jul; 38(7):813-9. PubMed ID: 10405498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder.
    Biederman J; Lopez FA; Boellner SW; Chandler MC
    Pediatrics; 2002 Aug; 110(2 Pt 1):258-66. PubMed ID: 12165576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ; Abikoff HB; Connor DF; Biederman J; Pliszka SR; Boellner S; Read SC; Pratt R
    Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Biederman J; Mick E; Surman C; Doyle R; Hammerness P; Harpold T; Dunkel S; Dougherty M; Aleardi M; Spencer T
    Biol Psychiatry; 2006 May; 59(9):829-35. PubMed ID: 16373066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
    Greenhill LL; Muniz R; Ball RR; Levine A; Pestreich L; Jiang H
    J Am Acad Child Adolesc Psychiatry; 2006 Jul; 45(7):817-23. PubMed ID: 16832318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder.
    Arnold LE; Lindsay RL; Conners CK; Wigal SB; Levine AJ; Johnson DE; West SA; Sangal RB; Bohan TP; Zeldis JB
    J Child Adolesc Psychopharmacol; 2004; 14(4):542-54. PubMed ID: 15662146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Objective and subjective measures of the pharmacodynamic effects of Adderall in the treatment of children with ADHD in a controlled laboratory classroom setting.
    Swanson J; Wigal S; Greenhill L; Browne R; Waslick B; Lerner M; Williams L; Flynn D; Agler D; Crowley KL; Fineberg E; Regino R; Baren M; Cantwell D
    Psychopharmacol Bull; 1998; 34(1):55-60. PubMed ID: 9564199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis.
    Marchetti A; Magar R; Lau H; Murphy EL; Jensen PS; Conners CK; Findling R; Wineburg E; Carotenuto I; Einarson TR; Iskedjian M
    Clin Ther; 2001 Nov; 23(11):1904-21. PubMed ID: 11768842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developmental aspects of psychostimulant treatment in children and adolescents with attention-deficit/hyperactivity disorder.
    Findling RL; Short EJ; Manos MJ
    J Am Acad Child Adolesc Psychiatry; 2001 Dec; 40(12):1441-7. PubMed ID: 11765290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.